Drug Trial Radar · NCT05090371
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Mar 2, 2022
Primary completion
Apr 13, 2027
Study completion Apr 13, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
OfatumumabDrug
3 loading doses followed by administration every 4 weeks as per label
Disease modifying treatment (DMT)Drug
Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving NEDA-3 (No Evidence of Disease Activity-3)Time frame: Months 3 to 15
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates PC
Birmingham, Alabama
North Central Neurology Associates PC
Cullman, Alabama
Radiant Research Chandler
Chandler, Arizona
Arizona Neuroscience Research LLC
Phoenix, Arizona
University of California at Los Angeles
Torrance, California
Neurology of Central FL Res Ctr
Altamonte Springs, Florida
S And D Clinical Research
Cape Coral, Florida
Homestead Assoc In Research Inc
Homestead, Florida
Neurology Associates PA
Maitland, Florida
Orlando Health Clinical Trials
Orlando, Florida
Emerald Coast Neurology
Pensacola, Florida
University Of South Florida
Tampa, Florida
Kootenai Health
Coeur d'Alene, Idaho
Neuro Medial Clinic of Central Louisiana
Alexandria, Louisiana
International Neurorehab Institute
Lutherville, Maryland
Reliant Medical Group
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Memorial Healthcare
Owosso, Michigan
University of Mississippi Medical Center
Jackson, Mississippi
St Barnabas Medical Center
Livingston, New Jersey
Jersey Shore University Medical Ctr
Neptune City, New Jersey
SUNY Upstate Medical Center
Syracuse, New York
University Of NC At Chapel Hill
Chapel Hill, North Carolina
Piedmont HealthCare
Charlotte, North Carolina
Velocity Clinical Research
Raleigh, North Carolina
Palmetto Clinical Research
Summerville, South Carolina
Sibyl Wray MD Neurology PC
Knoxville, Tennessee
Clinical Trial Network
Houston, Texas
Neuro Mind Clinical Trials Ltd Co
Katy, Texas
Covenant Medical Group
Lubbock, Texas
West Texas Cancer Center
Odessa, Texas
Tranquil Clinical Research
Webster, Texas
Sentara Neuroscience Institute
Virginia Beach, Virginia
Evergreen Health Multiple Sclerosis Center
Kirkland, Washington
Swedish Medical Center
Seattle, Washington
Aurora BayCare Medical Center
Green Bay, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Burnaby, British Columbia, Canada
Novartis Investigative Site
Vancouver, British Columbia, Canada
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.